Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer

Figures & data

Figure 1. Expression of MAGE-A antigens in relation to the mutational status of EGFR and KRAS genes and to the histologic subtype in resected NSCLC tumors. MAGE-A expression was assessed by immunohistochemistry in 177 resected Stage I-IIIA non-small cell lung cancer (NSCLC) of squamous cell carcinoma (n = 102) or adenocarcinoma (n = 75) types.⁹ The mutational status (WT, wild type; Mut, mutated) of the EGFR and KRAS genes was also assessed in the same tumors.⁹ MAGE-A expression is schematically represented in relation to the histologic tumor type and to EGFR and KRAS mutational status.

Ayyoub M, Memeo L, Alvarez-Fernandez E, Colarossi C, Costanzo R, Aiello E, Martinetti D, Valmori D. Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathological features and mutational status of EGFR and KRAS. Cancer Immunol Res 2014; In press; PMID:24866168

 PubMed Web of Science ®Google Scholar